Compare · BSX vs NVAC
BSX vs NVAC
Side-by-side comparison of Boston Scientific Corporation (BSX) and NorthView Acquisition Corporation (NVAC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and NVAC operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX carries a market cap of $64.27B.
- BSX has hit the wire 12 times in the past 4 weeks while NVAC has been quiet.
- BSX has more recent analyst coverage (25 ratings vs 0 for NVAC).
- Company
- Boston Scientific Corporation
- NorthView Acquisition Corporation
- Price
- -
- -
- Market cap
- $64.27B
- -
- 1M return
- +0.43%
- -
- 1Y return
- -56.40%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2022
- News (4w)
- 12
- 0
- Recent ratings
- 25
- 0
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
NorthView Acquisition Corporation
NorthView Acquisition Corporation does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It also intends to focus its search on businesses that are focused on healthcare sector. The company was incorporated in 2021 and is based in New York, New York. NorthView Acquisition Corporation is a subsidiary of NorthView Sponsor I, LLC.
Latest BSX
- Chairman, President & CEO Mahoney Michael F received a gift of 252,241 shares (SEC Form 4)
- SVP, Chief HR Officer O'Sullivan Miriam converted options into 3,871 shares and covered exercise/tax liability with 1,872 shares, increasing direct ownership by 11% to 19,565 units (SEC Form 4)
- Blackstone Life Sciences Announces $455 Million Collaboration to Co-Fund Development of Boston Scientific VITALYST™ Heart Pump for Patients with Cardiogenic Shock
- SEC Form 10-Q filed by Boston Scientific Corporation
- SIMPLAAFY study of the WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device meets primary endpoints
- Boston Scientific downgraded by TD Cowen with a new price target
- Penumbra, Inc. Reports Third Quarter 2026 Financial Results
- Boston Scientific downgraded by Oppenheimer
- Boston Scientific downgraded by Analyst with a new price target
- SEC Form 8-K filed by Boston Scientific Corporation
Latest NVAC
- Former Trump Administration VA Secretary Peter O'Rourke Sr. Joins Quantum Cyber's Board of Directors
- SEC Form 3 filed by new insider Asarpota Rajesh
- New insider Hwang Ben Chung-Bin claimed ownership of 844,228 shares (SEC Form 3)
- NorthView Acquisition Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Change in Shell Company Status, Other Events
- SEC Form DEF 14C filed by NorthView Acquisition Corporation
- SEC Form CERT filed by NorthView Acquisition Corporation
- SEC Form 8-A12B filed by NorthView Acquisition Corporation
- SEC Form 425 filed by NorthView Acquisition Corporation
- NorthView Acquisition Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 25-NSE filed by NorthView Acquisition Corporation